Press release
Lawsuit for Investors in shares of Exicure, Inc. (NASDAQ: XCUR) filed
A lawsuit was filed on behalf of investors in Exicure, Inc. (NASDAQ: XCUR) shares over alleged securities laws violations.
Investors who purchased shares of Exicure, Inc. (NASDAQ: XCUR) have certain options and for certain investors are short and strict deadlines running. Deadline: February 11, 2022. NASDAQ: XCUR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Chicago, IL based Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. On November 15, 2021, Exicure, Inc. filed a Form 12b-25 with the SEC stating that it could not timely file its quarterly report for the period ended September 30, 2021. It explained that the Company was investigating "a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia."
Shares of Exicure, Inc. (NASDAQ: XCUR) declined from $1.30 per share in October 2021, to $0.441 per share on November 23, 2021On November 15, 2021, after the market closed, Exicure filed a Form 12b-25 with the SEC stating that it could not timely file its quarterly report for the period ended September 30, 2021. It explained that the Company was investigating “a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia.”
On this news, the Company’s stock price fell $0.30, or 28%, to close at $1.07 per share on November 16, 2021, on unusually heavy trading volume.
The plaintiff claims that between March 11, 2021 and November 15, 2021, the Defendants failed to disclose to investors that there had been certain improprieties in Exicure’s preclinical program for the treatment of Friedreich’s ataxia, that, as a result, there was a material risk that data from the preclinical program would not support continued clinical development, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of Exicure, Inc. (NASDAQ: XCUR) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit for Investors in shares of Exicure, Inc. (NASDAQ: XCUR) filed here
News-ID: 2516030 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Exicure
Intratumoral Cancer Therapies Market Predicted to See Upsurge Through 2034, High …
DelveInsight's "Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Intratumoral Cancer Therapies, historical and forecasted epidemiology as well as the Intratumoral Cancer Therapies market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Intratumoral Cancer Therapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Intratumoral Cancer Therapies…
Spinal Muscular Atrophy Pipeline Assessment (2023) Covering Clinical Trials, Eme …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 18+ key pharma and biotech companies are working on 20+ pipeline drugs in the Spinal Muscular Atrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Spinal Muscular Atrophy Pipeline Insight,…
Neuronal Ceroid Lipofuscinoses Cln1 Market Statistical Forecast, Trade Analysis …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Neuronal Ceroid Lipofuscinoses Cln1 Market.
The Neuronal Ceroid Lipofuscinoses Cln1 Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production…
Investigation for Long-Term Investors in shares of Exicure, Inc. (NASDAQ: XCUR) …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Exicure, Inc.
Investors who are current long term investors in Exicure, Inc. (NASDAQ: XCUR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: XCUR stocks follows a lawsuit filed against Exicure, Inc. over…
Deadline on February 11, 2022 coming up in the Lawsuit for certain Investors in …
A deadline is coming up on February 11, 2022 in the lawsuit filed for certain investors of Exicure, Inc. (NASDAQ: XCUR) over alleged securities laws violations by Exicure, Inc.
Investors who purchased shares of Exicure, Inc. (NASDAQ: XCUR) have certain options and there are strict and short deadlines running. Deadline: February 11, 2022. NASDAQ: XCUR stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Investigation announced for Investors in Exicure, Inc. (NASDAQ: XCUR) over possi …
An investigation was announced concerning potential securities laws violations by Exicure, Inc. in connection with certain financial statements.
Investors who purchased shares of Exicure, Inc. (NASDAQ: XCUR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Exicure, Inc. (NASDAQ: XCUR) concerning whether a series of statements…
